Antiplatelet therapy and outcome in COVID-19: the Health Outcome Predictive Evaluation Registry

Santoro, Francesco1; Nunez-Gil, Ivan Javier2; Vitale, Enrica1; Viana-Llamas, Maria C.3; Reche-Martinez, Begona4; Romero-Pareja, Rodolfo5; Feltez Guzman, Gisela6; Fernandez Rozas, Inmaculada7; Uribarri, Aitor8; Becerra-Munoz, Victor Manuel9; Alfonso-Rodriguez, Emilio10; Garcia-Aguado, Marcos11; Huang, Jia12; Ortega-Armas, Maria Elizabeth13; Garcia Prieto, Juan F.14; Corral Rubio, Eva Maria15; Ugo, Fabrizio16; Bianco, Matteo17; Mulet, Alba18; Raposeiras-Roubin, Sergio19; Jativa Mendez, Jorge Luis20; Espejo Paeres, Carolina21; Albarran, Adrian Rodriguez22; Marin, Francisco23; Guerra, Federico24; Akin, Ibrahim25; Cortese, Bernardo26; Ramakrishna, Harish27; Macaya, Carlos2; Fernandez-Ortiz, Antonio28; Brunetti, Natale Daniele1

2021-10-01

10.1136/heartjnl-2021-319552

HEART   影响因子和分区

1355-6037

1468-201X

["Background Standard therapy for COVID-19 is continuously evolving. Autopsy studies showed high prevalence of platelet-fibrin-rich microthrombi in several organs. The aim of the study was therefore to evaluate the safety and efficacy of antiplatelet therapy (APT) in hospitalised patients with COVID-19 and its impact on survival.","Methods 7824 consecutive patients with COVID-19 were enrolled in a multicentre international prospective registry (Health Outcome Predictive Evaluation-COVID-19 Registry). Clinical data and in-hospital complications were recorded. Data on APT, including aspirin and other antiplatelet drugs, were obtained for each patient.","Results During hospitalisation, 730 (9%) patients received single APT (93%, n=680) or dual APT (7%, n=50). Patients treated with APT were older (74 +/- 12 years vs 63 +/- 17 years, p<0.01), more frequently male (68% vs 57%, p<0.01) and had higher prevalence of diabetes (39% vs 16%, p<0.01). Patients treated with APT showed no differences in terms of in-hospital mortality (18% vs 19%, p=0.64), need for invasive ventilation (8.7% vs 8.5%, p=0.88), embolic events (2.9% vs 2.5% p=0.34) and bleeding (2.1% vs 2.4%, p=0.43), but had shorter duration of mechanical ventilation (8 +/- 5 days vs 11 +/- 7 days, p=0.01); however, when comparing patients with APT versus no APT and no anticoagulation therapy, APT was associated with lower mortality rates (log-rank p<0.01, relative risk 0.79, 95% CI 0.70 to 0.94). On multivariable analysis, in-hospital APT was associated with lower mortality risk (relative risk 0.39, 95% CI 0.32 to 0.48, p<0.01).","Conclusions APT during hospitalisation for COVID-19 could be associated with lower mortality risk and shorter duration of mechanical ventilation, without increased risk of bleeding."]

COVID-19 pharmacology clinical

SCI

英语

其他

Cardiovascular System & Cardiology

Cardiac & Cardiovascular Systems

WOS:000722678600001

BMJ PUBLISHING GROUP

CLINICAL MEDICINE

Web of Science

1.Univ Foggia, Dept Med & Surg Sci, Foggia, Italy
2.San Carlos Univ Hosp, Dept Cardiol, Madrid, Spain
3.Hosp Gen Univ Guadalajara, Dept Intens Med, Guadalajara, Spain
4.Hosp Univ La Paz, Dept Emergency, Madrid, Spain
5.Hosp Univ Getafe, Dept Emergency, Getafe, Spain
6.Hosp Nuestra Senora Amer, Dept Cardiol, Madrid, Spain
7.Hosp Univ Severo Ochoa, Dept Cardiol, Leganes, Spain
8.Hosp Clin Univ Valladolid, Dept Cardiol, Valladolid, Spain
9.Hosp Clin Univ Virgen Victoria, Dept Cardiol, Malaga, Spain
10.Inst Cardiol & Cardiovasc Surg, Dept Cardiol, Havana, Cuba
11.Puerta Hierro Univ Hosp Majadahonda, Dept Cardiol, Majadahonda, Spain
12.Southern Univ Sci & Technol, Dept Cardiol, Affiliated Hosp 2, Shenzhen, Peoples R China
13.Hosp Gen Norte Guayaquil, Dept Cardiol, Guayaquil, Ecuador
14.Hosp Manises, Dept Emergency Med, Valencia, Spain
15.Hosp Univ Infanta Sofia, Dept Anesthesiol, Madrid, Spain
16.Sant Andrea Hosp, Dept Cardiol, Vercelli, Italy
17.San Luigi Gonzaga Univ Hosp, Orbassano & Rivoli Infermi Hosp, Div Cardiol, Rivoli, Italy
18.Hosp Clin Valencia, Dept Lung Dis, Valencia, Spain
19.Univ Hosp Alvaro Cunqueiro, Dept Cardiol, Vigo, Spain
20.Hosp Especialidades Fuerzas Armadas, Dept Cardiol, Quito, Ecuador
21.Hosp Univ Principe Asturias, Dept Cardiol, Madrid, Spain
22.Hosp Univ Juan Ramon Jimenez, Dept Cardiol, Huelva, Spain
23.Univ Murcia, Hosp Clin Univ Virgen Arrixaca, IMIB Arrixaca, Dept Cardiol, Murcia, Spain
24.Marche Polytech Univ, Univ Hosp Osped Riuniti, Cardiol & Arrhythmol Dept, Ancona, Italy
25.Univ Mannheim, Fac Med, Dept Med 1, Mannheim, Germany
26.Clin San Carlo, Dept Cardiol, Milan, Italy
27.Mayo Clin, Dept Cardiovasc & Thorac Anesthesiol, Rochester, MN USA
28.San Carlos Univ Hosp, Dept Cardiol, Madrid, Spain

Santoro, Francesco,Nunez-Gil, Ivan Javier,Vitale, Enrica,et al. Antiplatelet therapy and outcome in COVID-19: the Health Outcome Predictive Evaluation Registry[J]. HEART,2021.

Santoro, Francesco.,Nunez-Gil, Ivan Javier.,Vitale, Enrica.,Viana-Llamas, Maria C..,Reche-Martinez, Begona.,...&Brunetti, Natale Daniele.(2021).Antiplatelet therapy and outcome in COVID-19: the Health Outcome Predictive Evaluation Registry.HEART.

Santoro, Francesco,et al."Antiplatelet therapy and outcome in COVID-19: the Health Outcome Predictive Evaluation Registry".HEART (2021).